Tegaserod for constipation-predominant irritable bowel syndrome

Pharmacotherapy

Volumn 27, Issue 2, 2007, Pages 267-277

  Kale Pradhan, Pramodini B ^a,b   Wilhelm, Sheila M ^a,c  

^a WAYNE STATE UNIVERSITY   (United States)

^b ST JOHN HOSPITAL AND MEDICAL CENTER   (United States)

^c HARPER UNIVERSITY HOSPITAL   (United States)

Author keywords

5 HT4; 5 hydroxytryptamine; Constipation; HTF 919; Irritable bowel syndrome; Serotonin; Tegaserod; Zelnorm

Indexed keywords

CISAPRIDE; CYTOCHROME P450 1A2; CYTOCHROME P450 2D6; DEXTROMETHORPHAN; DIGOXIN; ERYTHROMYCIN; ORAL CONTRACEPTIVE AGENT; PARTIAL AGONIST; PLACEBO; SEROTONIN 4 AGONIST; TEGASEROD; THEOPHYLLINE; WARFARIN;

ABDOMINAL PAIN; AREA UNDER THE CURVE; CONSTIPATION; DIARRHEA; DIZZINESS; DRUG ABSORPTION; DRUG APPROVAL; DRUG BIOAVAILABILITY; DRUG DISTRIBUTION; DRUG DOSE COMPARISON; DRUG DOSE TITRATION; DRUG EXCRETION; DRUG MECHANISM; DRUG METABOLISM; DRUG SAFETY; DRUG STRUCTURE; DRUG TOLERABILITY; DRUG WITHDRAWAL; FLATULENCE; FOOD AND DRUG ADMINISTRATION; HEADACHE; HUMAN; INTESTINE ISCHEMIA; IRRITABLE COLON; LACTATION; NAUSEA; NONHUMAN; PATIENT SATISFACTION; PHARMACODYNAMICS; PREGNANCY; RECOMMENDED DRUG DOSE; REVIEW; SYNCOPE; SYSTEMATIC REVIEW;

CONSTIPATION; FEMALE; GASTROINTESTINAL AGENTS; HUMANS; INDOLES; IRRITABLE BOWEL SYNDROME; SEROTONIN 5-HT4 RECEPTOR AGONISTS; SEROTONIN RECEPTOR AGONISTS; TREATMENT OUTCOME;

EID: 33846794803     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: 10.1592/phco.27.2.267     Document Type: Review

References (44)

1. Novartis Pharmaceutical Corporation. Zelnorm (tegaserod) package insert. East Hanover, NJ; 2004.
2. Hoyer D, Clarke DE, Fozard JR, et al. VII. International union of pharmacology classification of receptors for 5-hydroxy-tryptamine (serotonin). Pharmacol Rev 1994;46:157-203.
3. 4 receptor in the human stomach. Jpn J Pharmacol 1999;79:493-6.
4. Borman RA, Burleigh DE. Human colonic mucosa possesses a mixed population of 5-HT receptors. Eur J Pharmacol 1996;309:271-4.
5. 4 receptor, in gastrointestinal motility. J Gastroenterol 2000;35:575-82.
6. 3 receptors. J Pharmacol Exp Ther 1999;288:93-7.
7. 4 receptor agonists initiate the peristaltic reflex in human, rat, and guinea pig intestine. Gastroenterology 1998;115:370-80.
8. 4 receptor agonist [abstr]. Gastroenterology 1999;117:A643.
9. Busti AJ, Murillo JR, Cryer B. Tegaserod-induced myocardial infarction: case report and hypothesis. Pharmacotherapy 2004;24:526-31.
10. Knudsen JF, Friedman B, Chen M, Goldwater JE. Ischemic colitis and sumatriptan use. Arch Intern Med 1998;158:1946-8.
11. Nguyen A, Camilleri M, Kost LJ, et al. SDZ HTF 919 stimulates canine colonic motility and transit in vivo. J Pharmacol Exp Ther 1997;280:1270-6.
12. 4-agonist (SDZ HTF 919) and its main metabolite in conscious dogs: effects on gastrointestinal motility and impaired gastric emptying [abstr]. Gastroenterology 1998;114(4):G3103.
13. 4 receptors mediating relaxation of canine isolated rectum circular smooth muscle. Brit J Pharmacol 1999;127:1431-7.
14. 4 receptor agonist. J Clin Pharmacol 1997;37:229-37.
15. 4 receptor agonist, in a model of slow colonic transit. Clin Pharmacol Ther 1997;62:546-55.
16. 4 receptor partial agonist, accelerates gastric emptying and gastrointestinal transit in healthy male subjects. Aliment Pharmacol Ther 2001;15(11):1745-51.
17. Prather CM, Camilleri M, Zinmeister AR, McKinzie A, Thomforde G. Tegaserod accelerates orocecal transit in patients with constipation-predominant irritable bowel syndrome. Gastroenterology 2000;118:463-8.
18. Appel-Dingemanse S, Horowitz A, Campestrini J, Osborne S, McLeod J. The pharmacokinetics of the novel promotile drug, tegaserod, is similar in healthy subjects - male and female, elderly and young. Aliment Pharmacol Ther 2001;15(7):937-44.
19. Swan SK, Zhou H, Horowitz A, et al. Tegaserod pharmacokinetics are similar in patients with severe renal insufficiency and in healthy subjects. J Clin Pharmacol 2003;43:359-64.
20. Appel-Dingemanse S, Hubert M, Alladina L, McLeod J. Pharmacokinetics and safety of SDZ HTF 919, a new promotile drug in healthy subjects and patients with hepatic cirrhosis [abstr]. Digestion 1998;59(suppl 3):EXhB5331.
21. Appel-Dingemanse S, Hirschberg Y, Osborne S, Pommier F, McLeod J. Multiple-dose pharmacokinetics confirm no accumulation and dose proportionality of the novel promotile drug tegaserod (HTF 919). Eur J Clin Pharmacol 2001;56:889-91.
22. 4 receptor agonist, following oral and intravenous administration. Br J Clin Pharmacol 1999;47:483-91.
23. Zhou H, Khalilieh S, Lau H, et al. Effect of meal timing not critical for the pharmacokinetics of tegaserod (HTF 919). J Clin Pharmacol 1999;39(9):911-19.
24. Vickers AE, Zollinger M, Dannecker R, Tynes R, Heitz F, Fischer V. In vitro metabolism of tegaserod in human liver and intestine: assessment of drug interactions. Drug Metab Dispos 2001;10:1269-76.
25. 4 agonist (HTF 919) improves symptoms in constipation- predominant irritable bowel syndrome (CIBS) [abstr]. Digestion 1998;59(suppl 3):A64.
26. 4 agonist HTF 919 improves symptoms of constipation predominant irritable bowel syndrome (CIBS) [abstr]. Digestion 1998;59(suppl 3):B5324.
27. 4 partial agonist, tegaserod, improves abdominal discomfort/pain and normalizes altered bowel function in irritable bowel syndrome (IBS) [abstr]. Am J Gastroenterol 1999;94(9):A2676.
28. 4 receptor partial agonist, relieves symptoms in irritable bowel syndrome patients with abdominal pain, bloating and constipation. Aliment Pharmacol Ther 2001;15:1655-66.
29. Novick J, Miner P, Krause R, et al. A randomized, double blind, placebo controlled trial of tegaserod in female patients with irritable bowel syndrome with constipation. Aliment Pharmacol Ther 2002;16:1877-88.
30. Kellow J, Lee OY, Chang FY, et al. An Asian Pacific, double blind placebo-controlled, randomized study to evaluate the efficacy, safety and tolerability of tegaserod in patients with irritable bowel syndrome. Gut 2003;2:671-6.
31. Nyhlin H, Bang C, Elsborg L, et al. A double-blind, placebo-controlled, randomized study to evaluate the efficacy, safety, and tolerability of tegaserod in patients with irritable bowel syndrome. Scand J Gastroenterol 2004;39:119-26.
32. Tack J, Muller-Lissner S, Bytzer P, et al. A randomized controlled trial assessing the efficacy and safety of repeated tegaserod therapy in women with irritable bowel syndrome with constipation. Gut 2005;54:1707-13.
33. Evans BW, Clark WK, Moore DJ, Whorwell PJ. Tegaserod for the treatment of irritable bowel syndrome. Cochrane Database Syst Rev 2004;(1):CD003960.
34. Muller-Lissner S, Koch G, Talley NJ, et al. Subject's global assessment of relief: an appropriate method to assess the impact of treatment on irritable bowel syndrome-related symptoms in clinical trials. J Clin Epidemiol 2003;56(4):310-16.
35. McLaughlin J, Houghton LA. The rationale, efficacy and safety evidence for tegaserod in the treatment of irritable bowel syndrome. Expert Opin Drug Saf 2006;5(2):313-27.
36. Shah SH, Jafri SW, Gul M, et al. Efficacy and tolerability of tegaserod in constipation dominant irritable bowel syndrome. J Coll Physicians Surg Pak 2004;14(1):21-4.
37. Lesbros-Pantoflickova D, Michetti P, Fried M, et al. Meta-analysis: the treatment of irritable bowel syndrome. Aliment Pharmacol Ther 2004:20:1253-69.
38. Chey WD, Olden K, Carter E, Boyle J, Drossman D, Chang L. Utility of the Rome I and Rome II criteria for irritable bowel syndrome in U.S. women. Am J Gastroenterol 2002;97(11):2803-11.
39. Fidelholtz J, Smith W, Rawls J, et al. Safety and tolerability of tegaserod in patients with irritable bowel syndrome and diarrhea symptoms. Am J Gastroenterol 2002;97(5):1176-80.
40. Tougas G, Snape WJ Jr, Otten MH, et al. Long-term safety of tegaserod in patients with constipation-predominant irritable bowel syndrome. Aliment Pharmacol Ther 2002;16(10):1701-8.
41. U.S. Food and Drug Administration. FDA talk: FDA updates Zelnorm labeling with new risk information. April 28, 2004. Available from http://www.fda.gov/bbs/topics/ANSWERS/2004/ANS01285.html. Accessed May 22, 2006.
42. Zhou H, Khalilieh S, Svendsen K, et al. Tegaserod coadministration does not alter pharmacokinetics of theophylline in healthy subjects. J Clin Pharmacol 2001;41(9):987-93.
43. Zhou H, Horowitz A, Ledford PC, et al. The effects of tegaserod (HTF 919) on the pharmacokinetics and pharmacodynamics of digoxin in healthy subjects. J Clin Pharmacol 2001;41(10):1131-9.
44. Drici MD, Ebert SN, Wang WX, et al. Comparison of tegaserod (HTF 919) and its main metabolite with cisapride and erythromycin on cardiac repolarization in the isolated rabbit heart. J Cardiovasc Pharmacol 1999;34:82-8.